- Details
- Neeraj Agarwal speaks with Zeynep Ozay about research on the impact of statins in patients with advanced prostate cancer treated with apalutamide. Dr. Ozay shares findings from a pooled patient-level analysis of the TITAN and SPARTAN trials, which included 2,190 patients receiving either ADT alone or ADT plus apalutamide. The multivariable analysis reveals that patients taking statins alongside ap...
|
- Details
- Zachary Klaassen interviews Stephen Freedland about a subanalysis from the EMBARK trial, which transformed treatment for high-risk biochemical recurrence in prostate cancer. Dr. Freedland describes how EMBARK demonstrated that enzalutamide, either as monotherapy or combined with ADT, significantly improved metastasis-free survival in patients with conventional imaging-negative disease and PSA doub...
|
- Details
- Alicia Morgans speaks with Nick James about the PATCH trial exploring estrogen patches as an alternative to standard androgen deprivation therapy for prostate cancer. Dr. James explains that using transdermal estrogen eliminates the thromboembolic risks of oral estrogen while offering better quality of life outcomes, including reduced fatigue and hot flashes, improved bone density, and favorable c...
|
- Details
- Neeraj Agarwal speaks with Martino Pedrani about integrating aggressive variant prostate cancer tumor suppressor gene (TSG) status into clinical decision-making for metastatic hormone-sensitive prostate cancer patients. Dr. Pedrani describes findings from a study showing that alterations in TP53, RB1, and PTEN genes predict worse progression-free and overall survival, independent of clinical chara...
|
- Details
- Neeraj Agarwal interviews Stacy Loeb about the IMPLEMENT study, which examines barriers to treatment intensification in metastatic hormone-sensitive prostate cancer. Dr. Loeb describes the mixed-methods approach combining qualitative interviews with a quantitative survey of over 300 oncologists and urologists. The study reveals distinct differences between academic and non-academic settings, with...
|
- Details
- Neeraj Agarwal speaks with Pedro Barata about findings regarding the under-utilization of genomic testing in metastatic castration-resistant prostate cancer. Dr. Barata shares data revealing that nearly half of patients aren't receiving homologous recombination repair (HRR) testing despite its clinical importance. Their discussion highlights that testing predominantly occurs at later disease stage...
|
- Details
- Oliver Sartor joins Zachary Klaassen to discuss the PRECISION data platform, a registry that contains over 65,000 advanced prostate cancer patients from 500 practices nationwide. Their analysis compares prompt versus deferred lutetium PSMA therapy (Pluvicto). Despite relatively short follow-up (median 17 months), findings show concordance between real-world and clinical trial outcomes. Patients re...
|
- Details
- Chad Tang discusses the WOLVERINE study, a meta-analysis of individual patient data from multiple randomized trials on oligometastatic prostate cancer. This collaborative effort pools data from STOMP, ORIOLE, ARTO, EXTEND, and COMET-SABR trials to evaluate metastasis-directed therapy. Results show significant improvements in progression-free survival, radiographic progression-free survival, and fr...
|
- Details
- Mike Wenzel joins Neeraj Agarwal to discuss a real-world comparison of cabazitaxel versus lutetium-177 PSMA radioligand therapy. Analyzing approximately 300 patients from the FRAMCAP database at the University of Frankfurt, results demonstrate significantly longer progression-free survival with lutetium (13 months versus 7 months) despite patients having more unfavorable baseline characteristics....
|
- Details
- Umang Swami joins Alicia Morgans to discuss real-world bone health agent utilization in metastatic castration-resistant prostate cancer. Analyzing the Flatiron Health database of 14,000 mCRPC patients from 250 centers nationwide, Dr. Swami reveals a concerning trend: after increasing from 56% to 65% between 2013-2015, bone hardener utilization has declined to approximately 46% in recent years. Thi...
|
